Aslan Pharmaceuticals announces expansion of collab with Zenyaku

ASLAN Pharmaceuticals announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo, to establish a framework for a succession of research projects to explore the differentiation of eblasakimab’s mechanism of action versus biologic therapies for atopic dermatitis, dupilumab and lebrikizumab. The results from this research collaboration will provide further insight into the differentiated receptor biology of targeting IL-13R versus IL-4R. The studies may also explain the long-lasting inhibition of disease severity biomarkers, such as TARC, observed after the end of the eblasakimab treatment period in earlier clinical studies2. This new agreement expands upon the commercial agreement that ASLAN signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.